Increased fracture risk after discontinuation of anti-osteoporosis medications among hip fracture patients: A population-based cohort study

被引:30
作者
Fu, Shau-Huai [1 ,2 ,3 ]
Wang, Chen-Yu [4 ,5 ,6 ]
Hung, Chih-Chien [1 ]
Lee, Chia-Che [3 ]
Yang, Rong-Sen [3 ]
Huang, Chuan-Ching [3 ]
Farn, Chui-Jia [3 ]
Lin, Wei-Hsin [3 ]
Chen, Ho-Min [7 ]
Hsiao, Fei-Yuan [4 ,5 ,8 ]
Lin, Jou-Wei [9 ]
Li, Chung-Yi [2 ,10 ,11 ]
机构
[1] Natl Taiwan Univ Hosp, Dept Orthoped, Yunlin Branch, Touliu, Yunlin, Taiwan
[2] Natl Cheng Kung Univ, Coll Med, Dept Publ Hlth, 138 Sheng Li Rd, Tainan 704, Taiwan
[3] Natl Taiwan Univ Hosp, Dept Orthoped, Taipei, Taiwan
[4] Natl Taiwan Univ, Coll Med, Sch Pharm, Taipei, Taiwan
[5] Natl Taiwan Univ, Coll Med, Grad Inst Clin Pharm, Taipei, Taiwan
[6] Natl Taiwan Univ Hosp, Dept Pharm, Yunlin Branch, Touliu, Yunlin, Taiwan
[7] Natl Taiwan Univ, Hlth Data Res Ctr, Taipei, Taiwan
[8] Natl Taiwan Univ Hosp, Dept Pharm, Taipei, Taiwan
[9] Natl Taiwan Univ Hosp, Cardiovasc Ctr, YunlinBranch, Touliu, Yunlin, Taiwan
[10] China Med Univ, Coll Publ Hlth, Dept Publ Hlth, Taichung, Taiwan
[11] Asia Univ, Coll Med & Hlth Sci, Dept Healthcare Adm, Taichung, Taiwan
关键词
osteoporosis; denosumab; bisphosphonate; discontinuation; fractures; VERTEBRAL FRACTURES; DENOSUMAB DISCONTINUATION; POSTMENOPAUSAL WOMEN; TRIAL; PERSISTENCE; REDUCTION; THERAPY; MEN;
D O I
10.1111/joim.13354
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background To compare the risks of major osteoporotic, vertebral, and non-vertebral fractures between patients who discontinued anti-osteoporosis medications. Methods We conducted a comparative effectiveness study with a nationwide population-based cohort study design. Patients aged >= 50 years admitted between 2012 and 2015 for incident hip fractures and receiving denosumab or bisphosphonates with sufficient compliance for at least 1 year were included. Patients were categorized into persistent or non-persistent denosumab or bisphosphonates users based on their subsequent use pattern. The main outcomes were subsequent hospitalizations for a major osteoporotic, vertebral or non-vertebral fracture. Multivariate, time-varying Cox proportional hazards model was used to evaluate the risk of major outcomes. Results Compared with persistent denosumab users, non-persistent denosumab users had a significantly higher risk of major osteoporotic fractures (hazard ratio [HR] = 1.60; 95% confidence interval [CI], 1.20-2.14), vertebral fractures (HR = 2.18; 95% CI, 1.46-3.24) and death (HR = 3.57; 95%CI, 2.63-4.84). However, the increased risk of fracture was not found in both persistent and non-persistent bisphosphonates users. Noteworthy, the increased risk of vertebral fractures in non-persistent denosumab users was more pronounced within 1 year post-discontinuation (HR = 2.90; 95% CI, 1.77-4.74) and among patients who discontinued from 2-year denosumab therapy (HR = 3.58; 95% CI, 1.74-7.40). Discussion Discontinuation of denosumab resulted in an increased risk of major osteoporotic fractures, especially vertebral fractures. The increased risk tends to reveal within 1 year post-discontinuation and be greater after a longer treatment duration. Notably, only fracture with hospitalization was identified as our research outcome, the real risk of osteoporotic fracture post discontinuation is believed to be higher, especially for vertebral fracture.
引用
收藏
页码:1194 / 1205
页数:12
相关论文
共 35 条
[1]   Bisphosphonate Drug Holiday and Fracture Risk: A Population-Based Cohort Study [J].
Adams, Annette L. ;
Adams, John L. ;
Raebel, Marsha A. ;
Tang, Beth T. ;
Kuntz, Jennifer L. ;
Vijayadeva, Vinutha ;
McGlynn, Elizabeth A. ;
Gozansky, Wendolyn S. .
JOURNAL OF BONE AND MINERAL RESEARCH, 2018, 33 (07) :1252-1259
[2]   Multiple clinical vertebral fractures following denosumab discontinuation [J].
Anastasilakis, A. D. ;
Makras, P. .
OSTEOPOROSIS INTERNATIONAL, 2016, 27 (05) :1929-1930
[3]   Clinical Features of 24 Patients With Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: Systematic Review and Additional Cases [J].
Anastasilakis, Athanasios D. ;
Polyzos, Stergios A. ;
Makras, Polyzois ;
Aubry-Rozier, Berengere ;
Kaouri, Stella ;
Lamy, Olivier .
JOURNAL OF BONE AND MINERAL RESEARCH, 2017, 32 (06) :1291-1296
[4]   Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports [J].
Aubry-Rozier, B. ;
Gonzalez-Rodriguez, E. ;
Stoll, D. ;
Lamy, O. .
OSTEOPOROSIS INTERNATIONAL, 2016, 27 (05) :1923-1925
[5]   The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT) [J].
Black, Dennis M. ;
Reid, Ian R. ;
Boonen, Steven ;
Bucci-Rechtweg, Christina ;
Cauley, Jane A. ;
Cosman, Felicia ;
Cummings, Steven R. ;
Hue, Trisha F. ;
Lippuner, Kurt ;
Lakatos, Peter ;
Leung, Ping Chung ;
Man, Zulema ;
Martinez, Ruvie Lou Maria ;
Tan, Monique ;
Ruzycky, Mary Ellen ;
Su, Guoqin ;
Eastell, Richard .
JOURNAL OF BONE AND MINERAL RESEARCH, 2012, 27 (02) :243-254
[6]   Effects of Denosumab Treatment and Discontinuation on Bone Mineral Density and Bone Turnover Markers in Postmenopausal Women with Low Bone Mass [J].
Bone, Henry G. ;
Bolognese, Michael A. ;
Yuen, Chui Kin ;
Kendler, David L. ;
Miller, Paul D. ;
Yang, Yu-Ching ;
Grazette, Luanda ;
San Martin, Javier ;
Gallagher, J. Christopher .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2011, 96 (04) :972-980
[7]   Ten years' experience with alendronate for osteoporosis in postmenopausal women [J].
Bone, HG ;
Hosking, D ;
Devogelaer, J ;
Tucci, JR ;
Emkey, RD ;
Tonino, RP ;
Rodriguez-Portales, JA ;
Downs, RW ;
Gupta, J ;
Santora, AC ;
Liberman, UA .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (12) :1189-1199
[8]   Discontinuation of denosumab and associated fracture incidence: Analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) Trial [J].
Brown, Jacques P. ;
Roux, Christian ;
Torring, Ove ;
Ho, Pei-Ran ;
Jensen, Jens-Erik Beck ;
Gilchrist, Nigel ;
Recknor, Christopher ;
Austin, Matt ;
Wang, Andrea ;
Grauer, Andreas ;
Wagman, Rachel B. .
JOURNAL OF BONE AND MINERAL RESEARCH, 2013, 28 (04) :746-752
[9]   Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension [J].
Cummings, Steven R. ;
Ferrari, Serge ;
Eastell, Richard ;
Gilchrist, Nigel ;
Jensen, Jens-Erik Beck ;
McClung, Michael ;
Roux, Christian ;
Torring, Ove ;
Valter, Ivo ;
Wang, Andrea T. ;
Brown, Jacques P. .
JOURNAL OF BONE AND MINERAL RESEARCH, 2018, 33 (02) :190-198
[10]   Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis [J].
Cummings, Steven R. ;
San Martin, Javier ;
McClung, Michael R. ;
Siris, Ethel S. ;
Eastell, Richard ;
Reid, Ian R. ;
Delmas, Pierre ;
Zoog, Holly B. ;
Austin, Matt ;
Wang, Andrea ;
Kutilek, Stepan ;
Adami, Silvano ;
Zanchetta, Jose ;
Libanati, Cesar ;
Siddhanti, Suresh ;
Christiansen, Claus .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (08) :756-765